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INTRODUCTION  
Octreotide (Sandostatin® Novartis, Berne, Switzerland) is a somatostatin analog 
approved for the treatment of acromegaly and gastrointestinal syndromes of hormone 
hypersecretion in Switzerland. Since somatostatin receptors (SSTR) are present on most 
meningiomas, octreotide has been suggested as a salvage treatment for patients with 
recurrent meningioma with presence of somatostatin receptors confirmed by octreotide 
SPECT or PET studies(1, 2). We report the case of a patient with metastatic 
somatostatin receptor-positive meningioma who developed multifocal CNS 
demyelination after octreotide therapy. 
 
CASE REPORT 
The female polyallergic (latex, non-steroidal anti-inflammatory drugs, hayfever, 
contrast agent) patient was diagnosed with a left sphenoidal meningioma in 1995 at the 
age of 37. After partial resection the tumor was classified as a WHO grade I 
meningotheliomatous meningioma and subsequently partially resected again 3 and 7 
years later due to progressive growth and subjected to postoperative radiotherapy with 
50Gy in June 1999. At the age of 52, a thoracic CT scan carried out for prolonged 
coughing showed multiple bilateral pulmonary nodules. Histological examination 
revealed SSTR-positive WHO grade I meningotheliomatous meningioma, compatible 
with pulmonary metastases. Octreotide scintigraphy of the head revealed positive 
signalling indicative of positive SSTR status of the primary meningioma. In preparation 
for planned salvage therapy the patient was subjected to low-dose subcutaneous 
octreotide treatment, which was given at 0.1 mg three times daily. This was 
discontinued on treatment day 25 since the patient developed new intermittent bilateral 
paraesthesia in the L3-L5 dermatomes on day 21 and the patient was admitted to our 
department. Magnetic resonance imaging (MRI) on day 28 after the first dose revealed 
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three new periventricular / subcortical and two, presumably new spinal (no previous 
spinal scan) T2-hyperintense lesions without contrast enhancement or diffusion 
restriction (Fig. 1). Electrophysiological examinations revealed normal nerve 
conduction studies of the left sural and tibial nerves, unremarkable visual evoked 
potentials, but an increased latency of the left tibial nerve on sensory evoked potentials.  
Cerebrospinal fluid (CSF) analysis during the acute phase and at 6 months follow-up [in 
brackets] were in accordance with chronic central nervous system (CNS) inflammation: 
normal cell count (4 [3]/μl), elevated IgG index (1.6 [1.06]; normal: <0.7), positive 
[positive] CSF oligoclonal bands (OCBs) (serum negative [negative]), elevated 
CSF/serum index for HSV IgG (5.07 [5.98]), measles IgG [6.62] and CMV IgG (4.06 
[4.16]; normal: 1.9), negative HCV and CMV PCR and a partly positive 
measles/rubella/zoster reaction (elevated CSF anti-measles and rubella IgG titres) 
(Tab.1).  
Cardiovascular examination revealed no signs of atheromatosis of the cranial vessels, an 
unremarkable serum lipid profile, no history of smoking, no cardiac arrhythmia, but a 
patent foramen ovale on echocardiography. Anti-CNS (anti-hu, -ri, -yo, -amphiphysin, -
cv2, -ta/-ma2, -ma, –recoverin) -antibodies and a vasculitis screening (anti-neutrophil 
cytoplasmic antibody, rheumatoid factor, MPO, PR3, anti-ß2, anti-cardiolipid, anti-U1-, 
snRNP-, anti-SS-A/B antibodies) revealed normal results.  
Since the discontinuation of octreotide the patient has not reported additional 
neurological symptoms, but paraesthesia still appear after exposure to heat, e.g. in the 
sauna. Over the last 2 years, without treatment, the primary cerebral meningioma 
showed gradual progression, while an additional pulmonary metastase was detected on 
repeated scans.   
 
DISCUSSION 
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We report the development of probably autoimmune-mediated multifocal demyelination 
after octreotide treatment in a patient with metastatic meningioma. The onset of clinical 
symptoms during treatment as well as MRI and CSF changes are suggestive of an 
immune process triggered by octreotide administration. In the light of a single clinical 
event with stable symptoms since the discontinuation of octreotide and negative 
antibody-screening, a paraneoplastic mechanism seems highly unlikely. Additional 
investigations showed no indication of an ischaemic, infectious or paraneoplastic 
etiology of the spinal and cerebral lesions. Sustained polyspecific intrathecal antibody 
production, elevated IgG index and positive OCBs however suggest a chronic 
autoimmune reaction as a putative cause for the multifocal cranial and spinal 
demyelination. The age of onset, unremarkable visual evoked potentials and the timing 
of onset of symptoms during the administration of octreotide do not exclude alternative 
demyelinating disorders such as multiple sclerosis (MS) or acute disseminated 
encephalomyelitis (ADEM), but appear less likely in the given context.    
So far no causative relation between octreotide administration and demyelination has 
been reported, although various possibly similar incidents appear to have occurred in 
the past. A search of the World Health Organization VigiBaseTM pharmacovigilance 
database (search terms: Sandostatin, Octreotide, demyelination, multiple sclerosis, 
accessed on Nov 2nd, 2010) revealed 57 cases of paraesthesia, 14 cases of peripheral 
neuropathy, 6 cases of encephalitis and 1 case of multiple sclerosis relapse in 
association with octreotide treatment since 1989(3).  
Antibody formation against octreotide was shown to occur in 77-81% of intranasally 
treated individuals within 9 months and in 27% of subcutaneously treated individuals 
within 3 years(4). Whether such an octreotide-specific immune response can lead to an 
autoimmune reaction within the CNS, e.g. by cross-reactivity against human 
autoantigens, is not known.  
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However, data indicate that somatostatin increases the susceptibility to develop 
experimental allergic encephalitis (EAE)(5) .  
The octreotide doses administered to the patient (0,1mg 3x daily) differed from the dose 
and schedule originally described as salgave therapy for SSTR positive meningioma 
(30mg every 28days) (1, 2). It is unclear in how far this might have increased the risk 
for this putative auto-immune mediated reaction. 
 
Conclusion 
This case indicates a possible risk for autoimmune mediated focal demyelination by 
octreotide treatment in polyallergic patients.   
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Figures & Tables 
Fig.1: Multifocal demyelination on cerebral and spinal MRI, current intracranial 
meningioma and pulmonary meningioma metastases:  
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Arrows highlight sites of demyelination: 4 months before the onset of paraesthesia 
unaffected tissue is shown in the right temporal, right occipital and left central regions 
of the brain (A, D, G), showing FLAIR-/T2-hyperintense lesions (without contrast 
enhancement on T1 or diffusion restriction – data not shown) during the acute episode 
including cervical and thoracic spinal cord (B, E, H, J, L) and at 4 months follow-up (C, 
F, I, K, M). The current intracranial meningioma adjacent to the tentorium and 
cavernous sinus (N) as well as superior orbital fissure (M) and parietal bone (M, N) are 
indicated by arrows (all courtesy of Prof. B. Schuknecht), as well confirmed bilateral 
pulmonary meningioma metastases (P, Q, R) (courtesy of Prof. J. Hodler).  
 
Tab. 1: Analysis of cerebrospinal fluid (CSF) during the acute episode and at six 
months follow-up: 
 
    
    
 
Table 1. Analysis of cerebrospinal fluid (CSF) during the acute episode and at six 
months follow-up 
 
 Acute episode 6 month follow-up Normal values 
Cell count (cells/μl) 4 3 0-4 
CSF/serum index of total IgG 1.6 1.05 <0.7 
Oligoclonal bands positive positive negative 
CSF/serum index of HSV-specific IgG 5.07 5.98 <1.9 
CSF/serum index of CMV-specific IgG 4.06 4.16 <1.9 
CSF/serum index of Measles-specific IgG n.a. 6.62 <1.9 
CSF/serum index of Rubella-specific IgG n.a. 3.2 <1.9 
CSF/serum index of VZV-specific IgG n.a. 0 <1.9 
HSV PCR negative n.a. negative 
CMV PCR negative n.a. negative 
 
 
